

# Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis

NCT06066450

---

Status	RECRUITING
Sponsor	Genoss Co., Ltd.
Enrollment	1,000 participants

## Key Eligibility Criteria

---

### Inclusion (3)

- Age 19 and above.
- Patients who have voluntarily decided to participate in this study and have provided written consent in accordance with the subject's agreement.
- Patients who have undergone percutaneous coronary intervention for stenosis within 5mm of the ostium of the coronary artery using OSFIT<sup>TM</sup> drug-eluting stents. (In case of simultaneous stent placement for other lesions, only Genoss<sup>TM</sup> drug-eluting stents should be used.)

### Exclusion (4)

- Patients with contraindications to stent treatment and antiplatelet therapy or who have hypersensitivity.
- Patients with a life expectancy of less than 1 year.
- Pregnant or lactating women, or those wishing to become pregnant.
- Patients with ST-elevation myocardial infarction (STEMI).

## Locations (1 total)

---

Ajou University Hospital, Suwon, South Korea